Osimertinib mesylate

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance. SYDNEY, June 25, 2026 /PRNewswire/ -- Racura Oncology Limited (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib in patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC). The first patient received RC220 at 50 mg/m2 by intravenous infusion. No adverse events were observed. HARNESS-1 is designed to test whether RC220, Racura's proprietary formulation of (E,E)-bisantrene, can be safely combined with osimertinib (Tagrisso®; AstraZeneca), a third-generation EGFR tyrosine kinase inhibitor (TKI) and standard-of-care therapy for EGFR-mutant NSCLC to delay or prevent TKI treatment resistance. Although EGFR TKIs have transformed outcomes for many patients with EGFR-driven lung cancer, acquired treatment resistance remains a central therapeutic challenge. Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "Dosing the first patient in HARNESS-1 is an important milestone for Racura and for the clinical development of RC220. The scientific rationale for this trial is grounded in the urgent need to address TKI therapeutic resistance in EGFR-mutant NSCLC. RC220 gives us the opportunity to explore whether targeting G4-DNA and RNA structures, including MYC-associated growth pathways, can delay EGFR TKI resistance arising and support a new therapeutic combination for patients treated with osimertinib. We are grateful to Associate Professor Surein Arulananda and the Monash Health team for enrolling and treating the first participant, and to the patients and families who make this research possible." Scientific Rationale EGFR-mutant NSCLC is a molecularly stratified lung adenocarcinoma subtype driven by constitutive EGFR kinase signaling and initial sensitivity to EGFR inhibition. However, responses to EGFR tyrosine kinase inhibitors, including osimertinib, are typically limited by acquired resistance, arising through heterogeneous mechanisms such as secondary EGFR alterations, bypass receptor tyrosine kinase activation, MAPK/PI3K pathway reactivation, oncogenic fusions, lineage plasticity, epithelial-to-mesenchymal transition and histologic transformation. RC220 is being developed to target the non-canonical G-quadruplex DNA and RNA structures enriched in oncogenic regulatory regions, including promoters, untranslated regions and highly transcribed loci. Stabilization of these structures can disrupt transcriptional and post-transcriptional control networks that sustain malignant proliferation, including silencing the c-MYC-regulated growth and survival pathways. HARNESS-1 is designed to evaluate the safety and tolerability of RC220 with continued osimertinib-mediated EGFR suppression, while generating pharmacokinetic, pharmacodynamic, molecular response and translational biomarker data. HARNESS-1 Trial Design HARNESS-1 is a multi-center Phase 1a/b clinical study in patients with EGFR-mutant NSCLC receiving osimertinib. The study includes an observational screening stage using ctDNA to help identify eligible patients and characterize tumor molecular status before treatment. The Phase 1a dose-escalation stage will evaluate RC220 administered by intravenous infusion on Day 1 of each 21-day cycle in combination with standard-of-care maintenance osimertinib. The first three dose levels will use single-patient cohorts at 50 mg/m2, 100 mg/m2 and 150 mg/m2, before progressing to larger cohorts to identify the maximum tolerated dose and an appropriate dose for further study. Between 12 and 40 patients are expected to participate in the dose-escalation stage. Following review of available safety and pharmacokinetic data, the study is expected to advance into a double-blind, randomized Phase 1b expansion stage. In this dose expansion stage, 40 patients will receive one of two RC220 dose levels in combination with osimertinib. Patients will be monitored for safety, pharmacokinetics and early signals of clinical activity, including progression-free survival, overall survival, ctDNA dynamics and changes in cancer-specific mutations. The first patient was treated by Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health in Clayton, Victoria. Additional clinical trial sites are expected to open in the coming months to support patient recruitment and study progress. Clinical Trial Information Further details about HARNESS-1, including open and recruiting sites, are available through the Australian and New Zealand Clinical Trial Registry at under trial code ACTRN12626000325303. Clinical trial inquiries may be directed to Racura Oncology at [email protected]. About RC220 & (E,E)-bisantrene RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene, is a clinical validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional silencing of the important cancer growth regulator c-MYC. About Racura Oncology Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer. Our lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent silencing of the important cancer growth regulator MYC. Racura is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, including a Phase 3 clinical program in acute myeloid leukemia (AML), a Phase 1 program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1 program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumor patients. Learn more at . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding expectations regarding clinical development and regulatory strategy and the Company's ability to deliver meaningful value to patients and shareholders. These statements relate to future events, future expectations, plans and prospects. Although Racura believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Racura has attempted to identify forward-looking statements by terminology including "believes", "estimates", "anticipates", "expects", "plans", "projects", "intends", "potential", "may", "could", "might", "will", "should", "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. Any forward-looking statements contained in this press release speak only as of its date. Racura undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. SOURCE Racura Oncology Limited 21% more press release views with Request a Demo

AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. Roche, a familiar sight at the top of PatientView’s cancer rankings, claimed first place ahead of AstraZeneca and Novartis. PatientView polled 505 cancer patient groups from December 2025 to March 2026 to assess perceptions of the biopharma industry and individual companies. Ranking companies they work with, respondents named (PDF) Roche, AstraZeneca and Novartis as the drugmakers with the best reputations. Last year, Servier took (PDF) the top spot ahead of Roche and Pfizer. AstraZeneca was absent from the top three last year and, unlike Novartis, it failed to make the podium when the patient groups ranked drugmakers they knew but didn’t necessarily work with. The return of AstraZeneca, which came (PDF) second in 2023, to the leaderboard reflects strength in two tumor types. Patient groups named AstraZeneca as the drugmaker with the best corporate reputation in breast and lung cancer. The tumor types are key therapeutic areas for AstraZeneca. In the first quarter, five of AstraZeneca’s seven best-selling products were cancer drugs (PDF). Four of the oncology medicines—Tagrisso, Imfinzi, Lynparza and Enhertu—are approved in forms of breast and lung cancer. Roche took second place on the breast and lung cancer rankings. Novartis claimed third in breast cancer, while Amgen occupied the final podium position in lung cancer. AstraZeneca came third in blood cancer, where it sells Calquence. Novartis topped the blood cancer table, followed by Johnson & Johnson. Pharma’s overall reputation among cancer patient groups has slipped in recent years. At 62%, the proportion of groups that said the industry has a “good” or “excellent” reputation was unchanged from last year but down on the 67% recorded two years in a row exiting the pandemic. Cancer drugmakers have a better reputation than the broader industry, which was graded at least good by 57% of groups. Drugmakers’ ability to innovate and to generate products that benefit cancer patients underpin positive perceptions of oncology companies. But the overall positivity in those areas masks some negative trends, including deteriorating perceptions of blood cancer drug developers’ ability to innovate. Longstanding negative views of cancer companies’ work on drug access and pricing were seen again in the latest poll.